Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic-drug specialist Teva Pharmaceutical (Nasdaq: TEVA) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Teva's business, and see what CAPS investors are saying about the stock right now.
Teva facts
Headquarters (Founded)
Petach Tikva, Israel (1901)
Market Cap
$44.8 billion
Industry
Pharmaceuticals
Trailing-12-Month Revenue
$12.2 billion
Management
CEO Shlomo Yanai (since 2007) CFO Eyal Desheh (since 2008)
Compound Annual Revenue and Net Income Growth (Over Past 5 Years)
25.2% and 45.3%
Cash/Debt
$1.8 billion/$6.8 billion
Competitors
Novartis (NYSE: NVS) Watson Pharmaceuticals (NYSE: WPI) Mylan (Nasdaq: MYL)
CAPS Members Bullish on TEVA Also Bullish on Continued...
Brian D. Pacampara is an investment expert and analyst for the Motley Fool.
Be the first to read Brian D. Pacampara's column. Sign up today and receive Townhall.com delivered each morning to your inbox.